Yuanyuan Zheng, Yanhui Yin, Hong Liu, Wenwen Gao, Qian Wang
{"title":"Rational Analysis of the Utilization of Pentoxifylline in a Tertiary Hospital: Central Hospital Affiliated to Shandong First Medical University.","authors":"Yuanyuan Zheng, Yanhui Yin, Hong Liu, Wenwen Gao, Qian Wang","doi":"10.2147/RMHP.S517679","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the rational use, safety, and economic implications of pentoxifylline in a hospital setting and provide recommendations for its appropriate clinical application.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 322 patients discharged from September to December 2020, who received pentoxifylline. Data were collected from the hospital information system, and the rationality of prescriptions was assessed based on drug instructions and guidelines. Adverse drug reactions (ADRs) were analyzed using CTCAE criteria. Economic evaluations included defined daily dose cost (DDDc) and incremental cost-effectiveness ratio (ICER) analyses.</p><p><strong>Results: </strong>The rational prescription rate for pentoxifylline was 38.51%, with the main irrationalities observed in indications (31.82%), dosage and usage (21.21%), contraindications (47.98%), and drug combinations (40.40%). Adverse reactions were reported in 12 cases (3.73%), primarily involving the nervous (75.00%) and digestive systems (41.67%). Most ADRs were mild (58.33%) or moderate (41.67%), with no severe cases observed. The DDDc of pentoxifylline was 143.4 yuan. Cost-effectiveness analysis demonstrated strong economic viability, with ICER values of 55.7 yuan per percentage point improvement in ulcer healing rate and 9.0 yuan per additional meter of pain-free walking distance, significantly below the willingness-to-pay threshold.</p><p><strong>Conclusion: </strong>Pentoxifylline demonstrates cost-effectiveness and manageable safety risks but has a low rational prescription rate, highlighting the need for improved clinical practices. Enhanced collaboration between pharmacists and medical staff, alongside stricter adherence to guidelines, is essential to optimizing its utilization.</p>","PeriodicalId":56009,"journal":{"name":"Risk Management and Healthcare Policy","volume":"18 ","pages":"2335-2350"},"PeriodicalIF":2.7000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256049/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Risk Management and Healthcare Policy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/RMHP.S517679","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aimed to evaluate the rational use, safety, and economic implications of pentoxifylline in a hospital setting and provide recommendations for its appropriate clinical application.
Methods: A retrospective analysis was conducted on 322 patients discharged from September to December 2020, who received pentoxifylline. Data were collected from the hospital information system, and the rationality of prescriptions was assessed based on drug instructions and guidelines. Adverse drug reactions (ADRs) were analyzed using CTCAE criteria. Economic evaluations included defined daily dose cost (DDDc) and incremental cost-effectiveness ratio (ICER) analyses.
Results: The rational prescription rate for pentoxifylline was 38.51%, with the main irrationalities observed in indications (31.82%), dosage and usage (21.21%), contraindications (47.98%), and drug combinations (40.40%). Adverse reactions were reported in 12 cases (3.73%), primarily involving the nervous (75.00%) and digestive systems (41.67%). Most ADRs were mild (58.33%) or moderate (41.67%), with no severe cases observed. The DDDc of pentoxifylline was 143.4 yuan. Cost-effectiveness analysis demonstrated strong economic viability, with ICER values of 55.7 yuan per percentage point improvement in ulcer healing rate and 9.0 yuan per additional meter of pain-free walking distance, significantly below the willingness-to-pay threshold.
Conclusion: Pentoxifylline demonstrates cost-effectiveness and manageable safety risks but has a low rational prescription rate, highlighting the need for improved clinical practices. Enhanced collaboration between pharmacists and medical staff, alongside stricter adherence to guidelines, is essential to optimizing its utilization.
期刊介绍：
Risk Management and Healthcare Policy is an international, peer-reviewed, open access journal focusing on all aspects of public health, policy and preventative measures to promote good health and improve morbidity and mortality in the population. Specific topics covered in the journal include:
Public and community health
Policy and law
Preventative and predictive healthcare
Risk and hazard management
Epidemiology, detection and screening
Lifestyle and diet modification
Vaccination and disease transmission/modification programs
Health and safety and occupational health
Healthcare services provision
Health literacy and education
Advertising and promotion of health issues
Health economic evaluations and resource management
Risk Management and Healthcare Policy focuses on human interventional and observational research. The journal welcomes submitted papers covering original research, clinical and epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, and extended reports. Case reports will only be considered if they make a valuable and original contribution to the literature. The journal does not accept study protocols, animal-based or cell line-based studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
